HYDROCORTISONE ACETATE- hydrocortisone acetate suppository 
Paddock Laboratories, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

Hydrocortisone Acetate
Suppositories 30 mg

DESCRIPTION

Each Hydrocortisone Acetate Suppository for rectal administration contains 30 mg hydrocortisone acetate in a hydrogenated cocoglyceride base.

Hydrocortisone acetate is a corticosteroid. The molecular weight of hydrocortisone acetate is 404.50. Chemically, hydrocortisone acetate is pregn-4-ene-3, 20 dione, 21- (acetyloxy)-11, 17- dihydroxy-, (11β)- with an empirical formula of C23H32O6 and the following structural formula:

Chemical Structure

CLINICAL PHARMACOLOGY

In normal subjects, about 26 percent of hydrocortisone acetate is absorbed when the hydrocortisone acetate suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces.

Topical steroids are primarily effective because of their anti-inflammatory, antipruritic and vasoconstrictive action.

INDICATIONS AND USAGE

Hydrocortisone Acetate Suppositories are indicated for use in inflamed hemorrhoids, post irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.

CONTRAINDICATIONS

Hydrocortisone Acetate Suppositories are contraindicated in those patients with a history of hypersensitivity to any of the components.

PRECAUTIONS

Do not use unless adequate proctologic examination is made.

If irritation develops, the product should be discontinued and appropriate therapy instituted.

In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, Hydrocortisone Acetate Suppositories should be discontinued until the infection has been adequately controlled.

Carcinogenesis

No long-term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.

Pregnancy Category C and Nursing Mothers

In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well-controlled studies in pregnant women.

It is not known whether this drug is excreted in human milk. Since many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Hydrocortisone Acetate Suppositories, a decision should be made whether to discontinue nursing or to discontinue taking the drug, taking into account the importance of the drug to the mother.

Until adequate studies in pregnant or lactating women have been conducted, this drug should be used during pregnancy or by nursing mothers only when clearly needed and when the potential benefits outweigh the potential risks to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

ADVERSE REACTIONS

The following local adverse reactions have been reported with Hydrocortisone Acetate Suppositories:

1.
Burning
2.
Itching
3.
Irritation
4.
Dryness
5.
Folliculitis
6.
Hypopigmentation
7.
Allergic Contact Dermatitis
8.
Secondary Infection

DRUG ABUSE AND DEPENDENCE

Drug abuse and dependence have not been reported in patients treated with Hydrocortisone Acetate Suppositories.

OVERDOSAGE

If signs and symptoms of systemic overdosage occur, discontinue use.

DOSAGE AND ADMINISTRATION

Usual dosage:

One suppository in the rectum twice daily morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to response.

HOW SUPPLIED

Hydrocortisone Acetate Suppositories are easy to open, color coded and available in cartons of:

12'sNDC 0574-7093-12

Store at controlled room temperature 15°- 30° C (59° - 86° F).

Paddock Laboratories, Inc.
Minneapolis, MN 55427

(04-05)

PRINCIPAL DISPLAY PANEL - 30 mg Packet Label

Hydrocortisone Acetate 30 mg
Suppository
(01) 10305747093122
Paddock Laboratories, Inc.
Minneapolis, MN 55427

PRINCIPAL DISPLAY PANEL - 30 mg Packet Label
HYDROCORTISONE ACETATE 
hydrocortisone acetate suppository
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0574-7093
Route of AdministrationRECTAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
HYDROCORTISONE ACETATE (UNII: 3X7931PO74) (HYDROCORTISONE - UNII:WI4X0X7BPJ) HYDROCORTISONE ACETATE30 mg
Product Characteristics
ColorWHITEScoreno score
ShapeBULLETSize35mm
FlavorImprint Code
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:0574-7093-1212 in 1 BOX
11 in 1 PACKET
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
UNAPPROVED DRUG OTHER07/07/2003
Labeler - Paddock Laboratories, LLC (967694121)
Establishment
NameAddressID/FEIBusiness Operations
Paddock Laboratories, LLC967694121MANUFACTURE(0574-7093)

Revised: 8/2012
 
Paddock Laboratories, LLC